Page 106 - Read Online

Rastogi. Hepatoma Res 2020;6:47 I http://dx.doi.org/10.20517/2394-5079.2020.35 Page 17 of 17

108. Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript
in fibrolamellar hepatocellular carcinoma. Science 2014;343:1010-4.
109. Riggle KM, Turnham R, Scott JD, Yeung RS, Riehle KJ. Fibrolamellar hepatocellular carcinoma: mechanistic distinction from adult
hepatocellular carcinoma. Pediatr Blood Cancer 2016;63:1163-7.
110. Kastenhuber ER, Lalazar G, Houlihan SL, Tschaharganeh DF, Baslan T, et al. DNAJB1-PRKACA fusion kinase interacts with beta-
catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. Proc Natl Acad Sci U S A 2017;114:13076-84.
111. Wilkens L, Bredt M, Flemming P, Kubicka S, Klempnauer J, et al. Cytogenetic aberrations in primary and recurrent fibrolamellar
hepatocellular carcinoma detected by comparative genomic hybridization. Am J Clin Pathol 2000;114:867-74.
112. Joseph NM, Tsokos CG, Umetsu SE, Shain AH, Kelley RK, et al. Genomic profiling of combined hepatocellular-cholangiocarcinoma
reveals similar genetics to hepatocellular carcinoma. J Pathol 2019;248:164-78.
113. Seehawer M, Heinzmann F, D’Artista L, Harbig J, Roux PF, et al. Necroptosis microenvironment directs lineage commitment in liver
cancer. Nature 2018;562:69-75.
114. Cancer Genome Atlas Research Network. Comprehensive and inte-grative genomic characterization of hepatocellular carcinoma.Cell
2017;169:1327-41.
115. Zhan P, Ji YN. Prognostic significance of TP53 expressionfor patients with hepatocellular carcinoma: a meta-analysis. Hepatobiliary Surg
Nutr 2014;3:11-7.